Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on April 29, 2025
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
GlobeNewswire
·
April 29, 2025
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- …
Atsena Therapeutics to Present at May Scientific Conferences
GlobeNewswire
·
April 29, 2025
DURHAM, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced it will present at the following …
ZenaTech’s ZenaDrone Subsidiary Will Showcase its Drones to US Defense Potential Customers at Major Upcoming Conferences
GlobeNewswire
·
April 29, 2025
VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and …
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
GlobeNewswire
·
April 29, 2025
– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on …
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
GlobeNewswire
·
April 29, 2025
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has …
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
GlobeNewswire
·
April 29, 2025
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune …
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
GlobeNewswire
·
April 29, 2025
CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no …
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
GlobeNewswire
·
April 29, 2025
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it …
Communiqué de presse :
GlobeNewswire
·
April 29, 2025
Quand chaque seconde compte : Sanofi, McLaren Racing et United Autosports s'unissent pour sensibiliser à la méningite aux 24 Heures du Mans Paris, le 29 avril 2025. Sanofi est fière de présenter une nouvelle étape significative dans sa mission de lutte …
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
GlobeNewswire
·
April 29, 2025
PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial …
Allies Against Slavery Releases Landmark State Human Trafficking Report
GlobeNewswire
·
April 29, 2025
AUSTIN, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Allies Against Slavery released its first-ever State Human Trafficking Report, analyzing anti-trafficking policies and federal prosecution patterns across all 50 states. The report offers policymakers, law …
Rover Further Expands into Europe
GlobeNewswire
·
April 29, 2025
LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Rover, a leading online marketplace for loving pet care, today announced it has launched in Denmark and Ireland, bringing its trusted services to millions of new pet parents. The expansion into two new countries …
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference …
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
GlobeNewswire
·
April 29, 2025
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first …
Denodo Platform 9.2 Delivers Intuitive Data Marketplace Experience Supported by Advanced Generative AI (GenAI) Capabilities
GlobeNewswire
·
April 29, 2025
PALO ALTO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Denodo, a leader in data management, announced the launch of Denodo Platform 9.2, adding new intuitive functionality to Denodo Platform 9.1, released in November, 2024, that builds on the Denodo …
Regeneron Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
April 29, 2025
First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22 First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024 First quarter 2025 EYLEA …
AgEagle Aerial Systems Receives Non-Compliance Notice from NYSE American and Makes NYSE American Section 610(b) Public Announcement
GlobeNewswire
·
April 29, 2025
WICHITA, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of best-in-class unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, …
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
April 29, 2025
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on …
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
GlobeNewswire
·
April 29, 2025
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a …
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
GlobeNewswire
·
April 29, 2025
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief …